Dernières nouvelles pour Kaspi.kz (NASDAQ:KSPI) Stock

Kaspi.kz

Kaspi.kz JSC is the payment, marketplace, and Fintech ecosystem in Kazakhstan. The firm provides interconnected technologically seamless products and services that help people to pay, shop and manage their finances. Its operating segment includes the Payments Platform that connects its customers, which consist of both consumers and merchants, to facilitate cashless, digital transactions, the Marketplace Platform that connects merchants and consumers enabling merchants to increase their sales and consumers to buy a broad selection of products and services offered by a variety of merchants, and Fintech Platform that enables customers to manage their personal finances online and access consumer finance and deposit products through the Kaspi.kz Super App.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54287100&amp;newsitemid=20250708472670&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=df60c87c0e441d8714fa335065a0bd03">Niagen Bioscience, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAGE#NASDAQ">NAGE</a>) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has entered into a worldwide exclusive commercial license agreement with the Haukeland University Hospital, Bergen, Norway. The agreement secures exclusive rights to a body of proprietary intellectual property, know-how, and data. These data are expected to support future regulatory filings for Conditional Marketing Authorization (CMA), Accelerated Approval (AA), and Marketing Authorization (MA) in the EU under European Medicines Agency (EMA) guidelines for the potential treatment of Parkinson`s Disease (PD) using the Company's patented nicotinamide riboside (Niagen&#xAE;) molecule.

Biotech

General

NAGE

Niagen Bioscience Enters Exclusive License Agreement With Haukeland University Hospital, Securing Exclusive Rights To A Body Of Proprietary IP, Know-How And Data

Merit Medical Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) announced a leadership transition on Monday, naming Martha Aronson as its next President and CEO, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46284655/merit-medical-names-martha-aronson-as-new-president-and-chief-executive-officer" rel="noreferrer noopener">effective October 3, 2025</a>.
Current CEO Fred Lampropoulos, who founded the company in 1987, will continue to serve as Chairman of the Board following the transition.
The Utah-based medical technology company also provided early revenue estimates for the second quarter, projecting between $380 million and $384 million in unaudited sales, a year-over-year rise of 12% to 14% compared to the same period in 2024. The analyst consensus estimate is pegged at $372.47 million. Constant currency growth is expected in the range of 11% to 13%.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46102914/fda-sounds-alarm-after-33-injuries-tied-to-medtronic-device-malfunction" rel="noreferrer noopener">FDA Sounds Alarm After 33 Injuries Tied To Medtronic Device Malfunction</a>
Following the announcement, Needham analyst Mike Matson reiterated a buy rating for Merit Medical Systems and maintained a $108 price forecast.
In the first quarter of 2025, Merit Medical Systems <a target="_blank" href="https://www.merit.com/wp-content/uploads/2025/04/MMSI-Q12025-Earnings-PressRelease-FINAL.pdf" rel="noreferrer noopener">delivered</a> a strong performance, with revenue climbing to $355.4 million, up 9.8% from the same period last year. On a constant currency basis, organic growth reached 6%, signaling solid underlying demand across its portfolio.
<h2 class="wp-block-heading">Leadership Change Marks New Chapter</h2>
Aronson brings with her a wealth of experience in international healthcare management. She previously held executive roles at companies like Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) and Hill-Rom Holdings Inc., and spent nearly two decades in leadership positions at Medtronic plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>).
She currently serves on the board of CONMED Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) and has held directorships at several other medical and tech firms. Lead Independent Director Dr. F. Ann Millner said the board was united in choosing Aronson after an exhaustive selection process.
Price Action: MMSI shares are trading higher by 2.12% to $93.05 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/07/46289610/palantir-co-founder-joe-lonsdale-wants-a-fda-overhaul-with-special-forces-style-ai-team-because-china-is-racing-to-outpace-us-in-biotech" target="_blank" rel="noreferrer noopener">Palantir Co-Founder Joe Lonsdale Wants A FDA Overhaul With Special Forces-Style AI Team Because China Is Racing To Outpace US In Biotech</a></li>
</ul>
Photo by PeopleImages.com &#8211; Yuri A via Shutterstock

Equities

News

Health Care

Markets

Movers

CNMD

MMSI

Merit Medical Names Medtronic Veteran Martha Aronson As Next CEO, Projects Strong Outlook

Galloper Gold Corp. (CSE:<a href="https://www.benzinga.com/stock/BOOM#CSE">BOOM</a>)(OTC:<a href="https://www.benzinga.com/stock/GGDCF#OTC">GGDCF</a>) (the "Company" or "Galloper") announces that, further to its news release of June 27, 2025, it has closed its non-brokered private placement issuing 5,000,000 common shares of the Company ("Shares") at a price of $0.05 per Share for aggregate gross proceeds of $250,000 (the "Private Placement") with Dundee Precious Metals Inc. (", Dundee", ("Dundee" - TSX:<a href="https://www.benzinga.com/stock/DPM#TSX">DPM</a>).
The Company did not pay any finder's fees or commissions in connection with the Private Placement.
The Company will utilize the proceeds from the Private Placement to fund exploration activities on it's flagship Glover Island property, to be commenced in Q3 2025 as well as funding the working capital needs of the Company.
All securities issued under the Private Placement to Dundee are subject to statutory hold periods expiring four months from the date of closing of the Private Placement.

Offerings

BOOM

Galloper Gold Corp Announces It Has Closed Its Non-Brokered Private Placement Issuing 5M Common Shares At A Price Of $0.05 Per Share For Aggregate Gross Proceeds Of $250K  With Dundee Precious Metals Inc

Mizuho analyst Dan Dolev initiates coverage on Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) with a Underperform rating and announces Price Target of $85.

Price Target

Initiation

Analyst Ratings

CRCL

Mizuho Initiates Coverage On Circle Internet Group with Underperform Rating, Announces Price Target of $85

Small Cap Consumer Research analyst Eric Beder reiterates Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Buy and maintains $23 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Guess, Maintains $23 Price Target

AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>, AMPGW))), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, announces the receipt of additional purchase orders nearing $3 Million as part of their $40M Letter of Intent (LOI) from Tier 1 MNO announced earlier this year. These purchase orders underscores AmpliTech's robust presence as a premier provider of ORAN 5G radio solutions.

AMPG

AMPGW

AmpliTech Group Receives Additional Purchase Orders Nearing $3M As Part Of $40M LOI From Tier 1 MNO

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

Cardio Diagnostics Enters Agreement With AGEPHA Pharma; AGEPHA To Supply Its LODOCO Medication For A Cardio Diagnostics-Sponsored Study Exploring PrecisionCHD Blood Test To Identify Inflammation Associated with Coronary Heart Disease

WLDS

Wearable Devices Partners With Media Exceed To Expand Mudra Brand And Mudra Link Distribution And Market Reach

UBS analyst Erika Najarian upgrades KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) from Neutral to Buy and raises the price target from $16 to $22.

Upgrades

UBS Upgrades KeyCorp to Buy, Raises Price Target to $22

Cooperation expected to drive targeted awareness and ecommerce sales to the brand through LQR House's proprietary marketing channels
MIAMI BEACH, FLORIDA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 8, 2025 / LQR House Inc. (the "Company" or "LQR House") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>), a niche ecommerce platform specializing in the spirits and beverage industry, today announced it has signed a marketing agreement with Montauk Distilling Co. to promote its cinnamon-flavored rum.
Under the agreement, LQR House will develop and execute a tailored three-months promotional marketing campaign designed to drive brand awareness and increase online sales through its own marketplace, CWSpirits.com. The campaign will leverage LQR House's proprietary digital tools, targeted advertising strategies, and extensive influencer network.
Montauk Distilling Co.'s cinnamon rum stands out for its unique flavor profile and strong consumer appeal, aligning perfectly with LQR House's focus on differentiated, high-quality beverage brands.
This cooperation represents another step in LQR House's ongoing mission to support emerging and craft spirits brands with targeted, data-driven marketing that directly connects products with customers.

LQR House Signs Marketing Agreement With Montauk Distilling To Promote Its Cinnamon-Flavored Rum

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines.
Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tempus.com%2Fnews%2Ftempus-introduces-its-ai-enabled-care-pathway-intelligence-platform-tempus-next%2F%3Fsrsltid%3DAfmBOopMnJZGkXiNZhmHVC6ONL6mQrVOtLkfTlzPXTtv7nrTmcB0o_gU&amp;esheet=54281597&amp;newsitemid=20250630158423&amp;lan=en-US&amp;anchor=Tempus+Next&amp;index=1&amp;md5=b4dcbf0b544c17631fca6d29cef377ec">Tempus Next</a>, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of patients across its network of provider sites, helping close critical care gaps for patients with lung cancer. Now, the platform will support five different biomarker testing gaps specific to breast cancer with the goal of helping physicians deliver guideline-directed medical care to eligible patients.
Tempus Next supports physicians administering guideline-based care by surfacing care gaps and identifying patients who may benefit from these guideline-based suggestions. The platform integrates multimodal data available in the patient's electronic medical record (EMR) with up-to-date clinical guidelines to support providers in delivering guideline-based care. As with lung cancer, clinical guidelines around breast cancer are continually evolving, and Tempus is working to help providers keep pace, starting at Mercy, which has already integrated Tempus Next for both breast and lung cancer into its EMR system to support patient care. Mercy has over 1,000 physician practice locations and outpatient facilities, more than 5,000 physicians and advanced practitioners serving patients across Arkansas, Illinois, Kansas, Missouri and Oklahoma.
"Staying current with rapidly evolving clinical guidelines—especially regarding biomarker testing like ESR1 mutations in metastatic breast cancer—remains a challenge for healthcare providers everywhere," Dr. Jay Carlson, DO, Medical Director of Oncology and Clinical Chair of Mercy Research. "Tools like Tempus Next support our team in identifying patients who may benefit from guideline-recommended testing, helping us deliver truly personalized cancer care."
"Keeping up with the complex and rapidly evolving clinical guidelines is a nearly impossible task for physicians, especially those in the community setting that are serving so many patients a day," said Chris Scotto DiVetta, Senior Vice President of AI Applications at Tempus. "We believe it is critical to partner with these providers, such as Mercy, to meet them where they are and design custom integrations that make it easier for their team to deliver optimized care."
The development of Tempus Next, including its breast cancer module, was funded by Tempus and one or more life sciences company sponsors.

Tempus Announces Expansion Of AI-Enabled Care Pathway Intelligence Platform Into Breast Cancer

An AI agent is software that can take actions independently. Unlike chatbots that just respond to questions, AI agents (virtual assistants) can access databases, run calculations, use tools, make decisions, and execute tasks without constant human supervision.
How they work: They combine <a href="https://www.mckinsey.com/featured-insights/mckinsey-explainers/what-is-generative-ai">foundation models</a> (like what powers <a href="https://www.benzinga.com/25/05/45253407/marketers-are-panicking-about-chatgpts-impact-on-seo-gumshoe-just-raised-2m-from-top-tech-veterans-to-solve-the-ai-search-crisis">ChatGPT</a>, Claude, or Copilot) with access to specific tools and knowledge bases. They follow instructions through a decision-making loop: observe the situation, plan what to do, execute actions, evaluate the outcome, and repeat. The complex technical framework involves prompt engineering, retrieval systems, memory management, and tool integration.
Companies start with a general-purpose framework and then customize it for specific domains and tasks. The level of customization varies dramatically. Some just connect GPT-4 to APIs and call it done. Others build complex systems with specialized knowledge and extensive guardrails.
<h2 class="wp-block-heading">Where AI Agents Fit in the Tech Landscape</h2>

<a href="https://www.benzinga.com/news/25/03/44066026/satya-nadella-says-ai-agents-will-replace-knowledge-work-but-theres-one-role-humans-will-always-need-to-play">AI agents</a> sit between simple bots and human decision-makers. Bots are rule-based, rigid systems that follow commands without adapting. They are fast but fragile, breaking when conditions change.
Humans, on the other hand, are highly adaptable. We handle complexity, nuance, and emotion, but we are limited by time, energy, and focus.
AI agents bridge the gap. They are more capable than bots &#8211; able to learn, adjust, and handle moderately complex tasks. But they are not human. They still struggle with context, ambiguity, and unpredictable situations.
In business, think of AI agents as decision virtual assistants. They analyze data, identify patterns, and suggest actions. They are great for repetitive, structured tasks, freeing up people to focus on what requires creativity, empathy, or strategic thinking.
However, they are still not fully autonomous. When the environment shifts or the stakes are high, human oversight is essential. You set the rules and boundaries; the agent works within them.
<h2 class="wp-block-heading">Planning vs. Reality</h2>

In theory, these systems work like this: They start by analyzing the main objective and breaking it down into smaller tasks. For example, a sales AI virtual assistant might begin by identifying past customer interactions as the first step. It then chooses the right tools and methods for each task, such as running database queries, using analytics frameworks, or calling external APIs. Based on the insights gathered, the system takes targeted actions to move toward its goal.
In reality, though, this process comes with limitations:
1) AI virtual assistants struggle with vague goals. Unlike humans, they cannot read between the lines or infer intent when objectives are not clearly defined, which is often the case in real-world business scenarios.
2) They miss the subtle business context. While humans intuitively understand that a 30% profit margin is healthy in one industry but problematic in another, AI agents lack that kind of contextual awareness.
3) An AI assistant is only as effective as the tools and data it can reach. If it needs customer sentiment data but cannot access the necessary customer records, it is essentially stuck.
4) AI agents follow decision trees, not judgment. They do not understand consequences or recognize when circumstances have fundamentally changed, especially in the security sphere, like a <a href="https://www.malwarefox.com/zero-day-attack/">zero-day attack</a>.
The most effective deployments today are narrow in scope and have well-defined success metrics like document processing, initial <a href="https://www.benzinga.com/news/25/05/45484599/ai-agents-can-be-10x-employees-ai-customer-support-chatbot-startup-founded-two-years-ago-seeks-100-million-at-a-1-5-billion-valuation">customer service</a> triage, or data extraction. The broader the objective, the more human oversight is needed.
<ol class="wp-block-list"></ol>
<h2 class="wp-block-heading">Bridging the Gap Between Efficiency and Failure</h2>
Let&#8217;s imagine two retail companies—Acme Analytics and Precision Insights—both decided to implement AI agents to improve their operations. But they took entirely different approaches.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<td>Aspect</td>
<td>Acme Analytics</td>
<td>Precision Insights</td>
</tr>
</thead>
<tbody>
<tr>
<td>Scope</td>
<td>Broad goal to &#8216;optimize all business processes&#8217;</td>
<td>Specific focus on inventory forecasting and pricing recommendations</td>
</tr>
<tr>
<td>Implementation Authority</td>
<td>Led by IT with little business input</td>
<td>A cross-functional team led by operations, with IT support</td>
</tr>
<tr>
<td>Success Metrics</td>
<td>No clear metrics, just a hope for more efficiency</td>
<td>Clear KPIs: 15% fewer stockouts, 5% margin gain</td>
</tr>
<tr>
<td>Human Oversight</td>
<td>Minimal oversight, AI is left to operate on its own</td>
<td>Structured review process: human reviews required for non-routine decisions</td>
</tr>
<tr>
<td>Training Data</td>
<td>Generic industry data only</td>
<td>Company-specific historical data plus industry benchmarks</td>
</tr>
<tr>
<td>Error Handling</td>
<td>No defined process for handling errors</td>
<td>Defined rollback procedures and human escalation paths</td>
</tr>
<tr>
<td>Tool Integration</td>
<td>Limited integration with key business systems</td>
<td>Full integration with inventory, POS, and supply chain systems</td>
</tr>
<tr>
<td>User Adoption</td>
<td>Rolled out with little training or support</td>
<td>Phased rollout with comprehensive training and feedback loops</td>
</tr>
</tbody>
</table>
</figure>
The key difference was not the AI itself; both used similar models. Precision Insights understood that AI is a tool, not a replacement for human judgment. They built around AI&#8217;s strengths in pattern recognition while accounting for its limitations in business context and nuance.
Results After Six Months
Acme Analytics:
The AI ignored key seasonal trends, leading to major inventory mistakes. Trust in the system collapsed, and employees stopped using it. The rollout was costly, with additional significant losses in revenue. In addition, several senior staff members resigned over the chaos.
Precision Insights:
Their focused AI reduced stockouts by several percentage points and improved profit margins. It flagged anomalies for human review instead of acting blindly. The entire investment paid off within just a couple of months. Employees welcomed the support, as the AI handled routine tasks while humans made complex decisions.
<h2 class="wp-block-heading">The Myth of Unlimited AI Agents: Why Focused Deployment Wins</h2>
A narrow focus is essential for AI agents. This is not a weakness; these systems only deliver value when applied to well-defined, structured processes and accurately reflect how real businesses operate.
Each process involves plenty of use cases and context-specific decisions. What works for inventory forecasting in retail will not apply to capacity planning in manufacturing without significant changes—different data, goals, and logic.
The first 3-5 AI virtual assistant implementations typically target the obvious, high-value, well-structured processes where the payoff is clear. After those are covered, each additional implementation faces higher complexity and lower returns.
Integrating additional AI agents is not plug-and-play; each agent requires custom connections, rules, and data, adding technical debt. Human oversight must also scale with each agent&#8217;s complexity and risk. As a relatively new technology for most companies, it is wise to manage only a handful at first and evaluate the results.
The promise of &#8220;AI agents for everything&#8221; is just another <a href="https://www.salesforce.com/blog/ai-agent-myths/">myth</a>. Real gains come from deploying several agents where decision logic is clear and structured, allowing humans to handle everything else.
<h2 class="wp-block-heading">Implementing AI Solutions</h2>

Most agentic AI systems are built on the same foundation: large language models connected to APIs. The difference between them often comes down to budget, scope, and how well they are implemented.
<ul class="wp-block-list">
<li>Custom Agents</li>
</ul>
AI agents follow learned rules and patterns based on company workflows. Setting them up takes time. They require detailed mapping of tasks and decision points. They handle routine decisions well, but humans step in when things get complex.
<ul class="wp-block-list">
<li>System Integration</li>
</ul>
AI agents connect with existing software systems through APIs or plugins. Their success depends on clean data, compatible systems, and stable infrastructure.
<ul class="wp-block-list">
<li>Multi-Agent Systems</li>
</ul>
Multiple agents can work together like an assembly line. Each one handles a specific task and passes it along. They work best when tasks are clearly defined, though troubleshooting issues can be challenging.
<h2 class="wp-block-heading">AI Virtual Assistant Trends to Watch</h2>

Here are the top <a href="https://hai.stanford.edu/news/better-benchmarks-for-safety-critical-ai-applications">AI trends</a> shaping the future of work:
<ul class="wp-block-list">
<li>Agents will start handling entire tasks with less guidance, but high-stakes decisions will still need human oversight.</li>
</ul>
<ul class="wp-block-list">
<li>They will not just wait for commands; they will detect issues, suggest actions, and sometimes act on their own. Be prepared to manage their choices.</li>
</ul>
<ul class="wp-block-list">
<li>Businesses will shift from general AI to agents trained for their specific, complex, and regulated workflows.</li>
</ul>
<ul class="wp-block-list">
<li>Teams of agents will collaborate on complex tasks, speeding up multi-step processes.</li>
</ul>
<ul class="wp-block-list">
<li>Agents will improve at understanding human intent and tone but will still struggle with emotional nuance.</li>
</ul>
<ul class="wp-block-list">
<li>Expect deeper integration with tools like CRMs, ERPs, and IoT—siloed agents will not cut it.</li>
</ul>

Opinion

Tech

AI Agents: Strengths, Weaknesses, and Business Implementation

Events

ACOG

Alpha Cognition To Present New Data On ZUNVEYL At Alzheimer's Association International Conference

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) is showing signs of a potential breakout, fueled by a massive spike in token burns, strategic partnerships <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">and on-chain activity.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
<td>Market Cap</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001186</td>
<td>&nbsp;$6.99 billion</td>
<td>+5.4%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1710</td>
<td>&nbsp;$25.7 billion</td>
<td>+6.4%&nbsp;</td>
</tr>
<tr>
<td>Pepe</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001002</td>
<td>&nbsp;$4.2 billion</td>
<td>+5.8%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Javon Marks points to a confirmed bullish divergence on SHIB's MACD, signaling a setup for a 180% surge back toward $0.000032. He believes this could be the start of a larger positive reversal for the meme coin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> (Shiba Inu) has confirmed a clear Bullish Divergence with its MACD and this points to a nearly 180% upside for prices back to $0.000032 and that may only be the start of a much larger positive reversal &#x1f4a5;&#8230; <a href="https://t.co/YmWAQbahKK">pic.twitter.com/YmWAQbahKK</a>
&mdash; JAVON&#x26a1;&#xFE0F;MARKS (@JavonTM1) <a href="https://twitter.com/JavonTM1/status/1941653689434787893?ref_src=twsrc%5Etfw">July 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
he Crypto Basic <a href="https://x.com/thecryptobasic/status/1942524175500910653">noted</a> that if crypto assets become more widely adopted, Shiba Inu stands to benefit significantly. 
With a current market dominance of 0.21%, they believe SHIB could capture 0.50% to 1% of the emerging digital economy. 
Statistics: Shibburn reported a 99,284.5% spike in SHIB's daily burn rate, driven primarily by a single transaction burning 1 billion SHIB roughly 16 hours ago. The 7-day burn rate is now up 1,807.3%, contributing to supply reduction and potential price support.
IntoTheBlock data shows Shiba Inu's daily active addresses moved higher by 9.3% while transactions greater than $100,000 are up from 21 to 24 in a single day.
Community News: The Shiba Inu team announced a <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46268405/shiba-inu-partners-with-new-token-lanchpad-to-take-on-solana-based-rival-that-birthed-fartcoin-just-the-beginning">new partnership</a> with token launchpad DegenSafe aimed at launching safer meme coin projects. 
The collaboration focuses on improving security and user protection in future token launches, a move that could elevate trust and utility across the SHIB ecosystem.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46246690/shiba-inu-jumps-5-in-a-single-day-is-a-bigger-rally-coming">Shiba Inu Jumps 5% In A Single Day: Is A Bigger Rally Coming?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Shiba Inu Burn Rate Explodes 99,280% In 1 Day: What Is Going On?

NANO Nuclear Signs MoU With UrAmerica Formalizing Discussions To Explore Development Across Argentina's Nuclear Fuel Supply Chain

WIIM

Aurora Mobile shares are trading higher after the company announced it expanded its Stablecoin use cases to SaaS, content, advertising, and hashnut-powered Web3 payments.

LCFY

Locafy shares are trading higher on possible continued strength after the company announced on Monday that it launched an AI SEO product suite.

Scotiabank analyst George Farmer downgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Sector Outperform to Sector Perform and lowers the price target from $12 to $9.2.

Downgrades

SAGE

Scotiabank Downgrades Sage Therapeutics to Sector Perform, Lowers Price Target to $9.2

SQNS

Sequans Communications shares are trading higher after the company announced it closed a $384 million strategic investment to launch a Bitcoin treasury initiative.

RLYB

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Legal

Press Releases

Kaspi.kz Investors: Please contact the Portnoy Law Firm to recover your losses. February 18, 2025 Deadline to file Lead Plaintiff Motion.

Earnings

Kaspi.kz 4Q and FY 2024 Financial Results

Notice of Annual General Meeting of Shareholders of Kaspi.kz

Kaspi.kz receives investment grade rating from Moody's

Kaspi.kz Files Annual Report on Form 20-F

Financing

Joint Stock Company Kaspi.kz issues USD denominated Eurobond

Kaspi.kz to acquire Rabobank Group's Turkish subsidiary Rabobank A.Ş.

Kaspi.kz: Announcement of AGM Results

Kaspi.kz to Announce 1st Quarter 2025 Financial Results on 12th May

Kaspi.kz 1Q 2025 Financial Results

KSPI

Ally Financial

Atlanticus Holdings Corporation - Common Stock

Atlanticus Holdings

American Express

Bread Financial Holdings, Inc. Common Stock

Bread Finl Hldgs

Credit Acceptance Corporation - Common Stock

Credit Acceptance

Capital One Financial Corporation Common Stock

Capital One Finl

Dave

Encore Capital Gr

Enova International

FirstCash Hldgs

FinVolution Group American Depositary Shares

FinVolution Group

Jiayin Group Inc. - American Depositary Shares

Jiayin Gr

Joint Stock Company Kaspi.kz - American Depository Shares

LendingClub

Lufax Holding Ltd American Depositary Shares, each representing two (2) Ordinary Shares

Comments

Kaspi.kz

Actualités

Dernières nouvelles pour Kaspi.kz (NASDAQ:KSPI) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL